Francesco Orlando

Francesco Orlando

Auto-generated profile, based on publicly available information

Francesco Orlando

Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GFGian Marco Franceschini
Gian Marco Franceschini
OQOrsetta Quaini
Orsetta Quaini
KMKei Mizuno
Kei Mizuno
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
HBHimisha Beltran
Himisha Beltran
Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification. Significance: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell–free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384

13 October 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
NBNicole Brighi
Nicole Brighi
DWDaniel Wetterskog
Daniel Wetterskog
OVOsvaldas Vainauskas
Osvaldas Vainauskas
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
GAGerhardt Attard
Gerhardt Attard
Purpose: Taxanes are life-prolonging treatments for patients with advanced prostate cancer. However, treatment resistance and lethal disease invariably develop. Here we used liquid biopsies to identify and characterize resistance to cabazitaxel. Experimental Design: We analyzed serial plasma from patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in a prospective biomarker study (NCT03381326, N = 97). ctDNA was studied using a bespoke, targeted genomic test (PCF_SELECT). Clinical and molecular variables were evaluated for associations with overall survival (OS) and radiographic progression-free survival (rPFS). Results: Patients categorized by median ctDNA fraction had progressively worse survival for ctDNA-negative versus -low versus -high patients (median OS: 26.8, 12.4, and 8.2 months; median rPFS: 8.0, 5.3, and 3.1 months). A ctDNA fraction increase at cycle 3 compared with patients who remained ctDNA negative associated with shorter OS [median, 7.5 vs. 29.9 months; HR, 4.60 (95% confidence interval, 2.06–10.28), P < 0.0001] and rPFS [median, 2.6 vs. 8.2 months; HR, 3.73 (95% confidence interval, 1.75–7.93), P < 0.0001]. Plasma DNA collected at progression on an androgen receptor pathway inhibitor was enriched for alterations in the androgen receptor gene, whereas after a taxane (docetaxel before cabazitaxel or after cabazitaxel), there was enrichment of copy-number gains of genes sited on chromosome 3 (ATR, PIK3CB, MLH1, and FANCD2) or involved in cell cycle regulation, including mutually exclusive alterations in CCND1 and CDKN1B. Conclusions: Sequential liquid biopsy identifies ctDNA features associated with treatment benefit in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. There was overlap of gene alterations selected for at progression on docetaxel or cabazitaxel, in part explaining cross-resistance.

13 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
PGPaola Gasperini
Paola Gasperini
Alessandro AlaimoAlessandro Alaimo
Alessandro Alaimo
BSBlerta Stringa
Blerta Stringa
YCYoon-Mi Chung
Yoon-Mi Chung
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis
The biological mechanisms underlying the cooperation between germline genetic variants and somatic mutations during carcinogenesis are rarely elucidated. In this study, characterizing isogenic prostate cancer cell lines, we dissected the interplay between a germline variant at the 7p14.3 locus (rs1376350, G>A) and early recurrent prostate cancer–specific mutation in the speckle-type POZ protein (SPOP) gene across human prostate adenocarcinomas. The transcriptomes of multiple edited models pointed to GLI3 and the Hedgehog signaling pathway in a genotype-specific manner, whereas SPOP mutation and androgen receptor stimulation promote GLI3 accumulation in the full-length, transcriptionally active form. This, in turn, triggers the cell-autonomous production of steroids that prostate cancer relies on, in line with the enhanced responsiveness of SPOP-mutated prostate cancer to androgen deprivation therapy. These data demonstrate that germline variants dictate prostate cancer somatic evolution and suggest opportunities to jointly model germline–somatic relationship to help untangle the complexity of human cancer. Significance: Significant heritability is observed for common cancer types worldwide. The molecular mechanisms by which inherited genetics facilitate cancer initiation might transit through its cooperation with specific somatic events that then dictate the tumor features. Through a germline–somatic tandem leading to steroid biosynthesis, we suggest a paradigm to study cancer initiation.

16 September 2026 in iScience
Verified
Journal Article
Open access
ICIlaria Cherchi
Ilaria Cherchi
FOFrancesco Orlando
Francesco Orlando
OQOrsetta Quaini
Orsetta Quaini
MPMarta Paoli
Marta Paoli
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis

1 March 2024
Verified
Other
Open access
GFGian Marco Franceschini
Gian Marco Franceschini
OQOrsetta Quaini
Orsetta Quaini
KMKei Mizuno
Kei Mizuno
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
HBHimisha Beltran
Himisha Beltran
Supp. Fig. 1 Differential methylation across prostate cancer disease states Supp. Fig. 2 NEMO panel design Supp. Fig. 3 Tumor content estimation with a minimal set of informative regions Supp. Fig. 4 Scoring CRPC-NE in circulation with the phenotype evidence (PE) score Supp. Fig. 5 Probing the CRPC spectrum with NEMO Supp. Fig. 6 Clinical utility of the NEMO assay Supp. Fig. 7 Copy number estimation using the NEMO assay